Nothing really meaningful, …
04/08/22 -"… but this could last into the next business year. We have moderately reduced our profitability expectations for the current and coming business years as we believe the mix of supply shortages and ..."
Pages
72
Language
English
Published on
04/08/22
You may also be interested by these reports :
30/10/26
Amplifon’s Q3 sales met expectations, while adjusted EBITDA missed. All regions recorded growth. Profitability improved, but full-year guidance ...
29/10/26
Clariane’s Q3 confirmed the operating turnaround: organic growth accelerated to 4.9%, occupancy reached 93% and France finally joined the party. The ...
28/10/26
The change in our NAV calculation reflects a change of analyst covering the stock. Our NAV/SOTP valuation is now based on a new breakdown separating ...
27/10/26
Despite some near-term caution (discussed in the EPS section), we continue to see sizeable upside for bioMerieux, supported by its dominance in ...